Tin tức & Cập nhật

A retrospective study spanning 25 years has shown that intravenous (IV) iron therapy in hospitalized patients with iron-deficiency anaemia and acute infections is associated with a lower risk of death.

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).